Search Medical Condition
Please enter condition
Please choose location

New Windsor, New York Clinical Trials

A listing of New Windsor, New York clinical trials actively recruiting patient volunteers.

RESULTS

Found (15) clinical trials

SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study

This is a phase 2a, proof-of-concept, 26-week, double-blind, multicenter, randomized, parallel group, placebo-controlled study to compare the efficacy and safety of treatment with SUVN-502 to placebo treatment in subjects with moderate Alzheimer's disease receiving donepezil HCl (10 mg qd) and either memantine HCl (10 mg twice daily [bid]) or Namenda ...

Phase

0.0 miles

Learn More »

This clinical trial is provided by TrialReach. The research study is evaluating a new medicine for type 2 diabetes for patients whose diabetes is not well controlled with their current therapy. The study medicine is being evaluated to see if it can help in the management of type 2 diabetes ...

Phase

0.0 miles

Learn More »

A 6-month Clinical Study to Evaluate the Effect of a Digital Disease Management Tool in Patients With T2DM

Type 2 diabetes mellitus (T2DM) is a complex, chronic disease that requires a comprehensive treatment plan aimed at meeting multitude therapeutic targets associated with micro- and macro-vascular risk reduction. There is evidence that patient support in various forms can have a significant positive impact on adherence to treatment and the ...

Phase N/A

0.0 miles

Learn More »

Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS

This is an event driven study to reach statistical power given all other assumptions. Subjects will visit the clinic 1 month after randomization and at regular intervals thereafter. Additionally, for any subject prematurely discontinuing study medication, assessments will be conducted every 6 months for the collection of study endpoints. Those ...

Phase

1.73 miles

Learn More »

Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment

This is a Phase III, randomized, double-blind, placebo-controlled, parallel group, multi-center, efficacy and safety trial of AM-111 in the treatment of subjects suffering from severe to profound idiopathic sudden sensorineural hearing loss. The active pharmaceutical ingredient of AM-111 is a JNK inhibitor (D-JNKI-1), a synthetic peptide consisting of 31 D-amino ...

Phase

1.73 miles

Learn More »